Searched for
TYPE2 DIABETES
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Hair loss due to soft drinks: Hair transplant surgeon explains whether drinking soda with meals can make you go baldCold drink causing hair loss: Daily cold drink habits might affect hair health. Doctors note a link between sugary beverages and conditions...
- Weight-loss drugs trim UK food bills by $1 billionHouseholds with at least one user of GLP-1 weight-loss drugs bought 299 million fewer food items in the year after adoption of the medicati...
- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
- Sleeping over 8 hours daily? Senior Neurologist at Apollo Hospitals explains its underlying health issues and potential risksAre you sleeping more than 8 hours? New research has revealed that a study of nearly 500,000 people found a 'sweet spot' of 6.4 to 7.8 hour...
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...
- Stock picks of the week: 6 stocks with consistent score improvement and upside potential of up to 29%At a time when there are so many headwinds for the markets, it is tough to imagine that things can get better. But sentiment is a fickle th...
- Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concernsThe Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approva...
- Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block dealShares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece o...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Bloating, constipation, poor digestion? Oxford-certified celebrity nutritionist shares 5 common superfoods you can easily find in your grocery storeDigestive issues like bloating and constipation are common. Mumbai-based nutritionist Suman Agarwal highlights five superfoods for better g...
- The supplement your doctor hasn't mentioned yet could be quietly fighting type 2 diabetes - here's everything you need to knowFish oil benefits for type 2 diabetes: Fish oil supplementation reduced insulin resistance and improved glucose tolerance in non-obese diab...
- Homeopathy doctor shares simple tips to reduce facial and belly fat; says your future self will thank youHealth experts warn that facial puffiness and belly fat, particularly visceral fat, are serious health indicators. Dr. Sayajirao Gaikwad em...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Insurer denies Rs 20 lakh life insurance claim over diabetes non-disclosure; woman fights back and wins; here’s whyA Delhi woman's Rs 20 lakh life insurance claim, denied due to alleged non-disclosure of diabetes and kidney diseases, was upheld by the St...
- Stocks in news: ITC, Nykaa, Lenskart, Ola Electric, IndusInd BankMarkets saw a volatile session with Nifty trading below the 23,800-24,000 resistance zone, though select heavyweight buying limited downsid...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...
- Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in CanadaDr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...
Load More
